416 related articles for article (PubMed ID: 11148402)
1. [What vascular events suggest a myeloproliferative disorder?].
Hachulla E; Rose C; Trillot N; Caulier-Leleu MT; Pasturel-Michon U
J Mal Vasc; 2000 Dec; 25(5):382-387. PubMed ID: 11148402
[TBL] [Abstract][Full Text] [Related]
2. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
3. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
4. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
5. Erythromelalgia--a thrombotic complication in chronic myeloproliferative disorders.
Tarach JS; Nowicka-Tarach BM; Matuszek B; Nowakowski A
Med Sci Monit; 2000; 6(1):204-8. PubMed ID: 11208311
[TBL] [Abstract][Full Text] [Related]
6. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
Cucuianu A; Stoia M; Farcaş A; Dima D; Zdrenghea M; Paţiu M; Olinic D; Petrov L
Rom J Intern Med; 2006; 44(4):397-406. PubMed ID: 18386616
[TBL] [Abstract][Full Text] [Related]
7. The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
van Genderen PJ; Leenknegt H; Michiels JJ
Semin Thromb Hemost; 1997; 23(4):385-9. PubMed ID: 9263356
[TBL] [Abstract][Full Text] [Related]
8. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A
Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
[TBL] [Abstract][Full Text] [Related]
9. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
10. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
[TBL] [Abstract][Full Text] [Related]
11. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
Landolfi R; Di Gennaro L; Falanga A
Leukemia; 2008 Nov; 22(11):2020-8. PubMed ID: 18800144
[TBL] [Abstract][Full Text] [Related]
12. Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Gadisseur A; Lam KH; De Raeve H; Schroyens W
Acta Haematol; 2015; 133(1):56-63. PubMed ID: 25116182
[TBL] [Abstract][Full Text] [Related]
13. Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia.
Kim KT; Sohn SI; Cho KH
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):913.e9-10. PubMed ID: 22305797
[TBL] [Abstract][Full Text] [Related]
14. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
Landolfi R; Cipriani MC; Novarese L
Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
Murphy S
Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
[TBL] [Abstract][Full Text] [Related]
16. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
[TBL] [Abstract][Full Text] [Related]
17. Bilateral adrenal swelling as a cause of chest, back, and upper abdominal pain in essential thrombocythemia and polycythemia vera is due to microvascular ischemic thrombosis rather than to hemorrhage.
Michiels JJ; Berneman Z; Schroyens W; Krestin GP
Ann Hematol; 2002 Dec; 81(12):691-4. PubMed ID: 12483364
[TBL] [Abstract][Full Text] [Related]
18. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
[TBL] [Abstract][Full Text] [Related]
19. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
[TBL] [Abstract][Full Text] [Related]
20. Erythromelalgia and vascular complications in polycythemia vera.
Michiels JJ
Semin Thromb Hemost; 1997; 23(5):441-54. PubMed ID: 9387203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]